Trial Profile
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 21 Mar 2023 Results of post-hoc pooled analysis assessing the disease improvement and clearance of palmoplantar PsO in the palms and soles of patients with moderate-to-severe plaque PsO and baseline palmoplantar PsO who were treated with ixekizumab for up to 5 years across 6 clinical trials (NCT01474512, NCT01597245, NCT01646177, NCT03364309, NCT02561806 and NCT03073200), presented at the American Academy of Dermatology annual Meeting 2023.
- 25 Apr 2021 Primary endpoint (Proportion of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) from Baseline) has been met.
- 25 Apr 2021 Primary endpoint (Proportion of Participants with a static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement from Baseline) has been met according to the results presented at the American Academy of Dermatology Virtual Meeting Experience 2021